Inhibition of T-cell-mediated immune response via the PD-1/PD-L1 axis in cholangiocarcinoma cells

Cholangiocarcinoma (CCA) is a malignant biliary tract epithelium tumor. The programmed death-1 (PD-1)/programmed receptor-ligand 1 (PD-L1) signaling pathway has been implicated as an immune escape mechanism in several cancers. The present study aimed to assess the expression of PD-L1 on human CCA cell lines and its potential role in suppressing CD8(+) T- cell function. A panel of intrahepatic CCA cell lines was evaluated for immune regulatory checkpoint ligands and inflammation markers. Effects of pro-inflammatory cytokine, interferon gamma (IFN-gamma), on the expression of immune regulatory checkpoint ligands and inflammation markers were determined. The PD-L1 function was measured by co-culturing CCA cells with lymphocytes. Most of the selected Thai CCA cell lines, including HuCCA-1, RMCCA-1, KKU-100, and KKU-213, expressed higher PD-L1 than normal cholangiocyte MMNK-1 and ANK-1 cells. Both PD-L1 and cyclooxygenase-2 (COX-2) expressions were highest in HuCCA-1 cells. A 48 h treatment with IFN-gamma increased the expression of PD-L1 and COX-2 in CCA cells. The expression of CTLA-4 ligands, including H7-1 and H7-2, did not change after IFN-gamma treatment. Rofecoxib, a specific COX-2 inhibitor, mitigated IFN-gamma-induced PD-L1 expression. After 48 h co-incubation, CD8(+) T-cell apoptosis was increased as compared to the control group. Pretreatment of CCA cells with IFN-gamma further increased CD8(+) T-cell apoptosis. Pembrolizumab, an anti-PD-1 antibody, mitigated CCA cell escape phenomenon. The inhibition of T-cell-mediated immune response via the PD-Ll/PD-1 axis are evidenced in intrahepatic CCA. Immunotherapy with checkpoint inhibitor offers a potentially therapeutic strategy for CCA patients; however, further in vivo and clinical studies are required.

Automated summary

The PD-L1/PD-1 axis inhibits T-cell-mediated immune response in intrahepatic cholangiocarcinoma (CCA), leading to immune evasion. Using an anti-PD-1 antibody may be a potential therapeutic strategy, but further research is needed for validation.